,10 These observations support the hypothesis that VEGF is the main pathologic driver in retinal diseases and that selective inhibition of mediators downstream of VEGF activation does not provide additional clinical benefit compared to the use of anti-VEGF agents alone. The gene discussed is VEGFA; the disease is Abnormal retinal morphology.